43 0 2

Partnering

MacroGenics is pursuing alliances to participate in development of its proprietary product candidates and technology platforms.

Learn more

Company Highlights

  • Robust pipeline in oncology, autoimmunity and infectious diseases
  • Partners include Boehringer Ingelheim, Pfizer and Servier
  • Fully-integrated biologics capabilities across product development process 
  • Strong financial position and blue-chip investor base
  • Experienced management team and highly collaborative corporate culture 
Learn more

Overview

Since its founding in 2000, MacroGenics has applied its world-class antibody capabilities to create life-changing medicines. The company’s innovative product candidates leverage its fully-integrated capabilities and its multiple, proprietary technology platforms.

Learn more

In the News

2007 News Archive

December 01, 2007 | Nature Biotechnology
Antivirals Become A Broader Enterprise

October 19, 2007 | Washington Post
Rockville Firm Deals Drug Rights to Lilly

October 19, 2007 | BioWorld Today
MacroGenics, Lilly Ink $1B Deal For Diabetes Drug Teplizumab

October 18, 2007 | Washington Business Journal
MacroGenics To Sell Rights To Lead Product To Eli Lilly

August 03, 2007 | Washington Business Journal
MacroGenics Begins Final Testing Of Diabetes Drug

January 04, 2007 | Washington Business Journal
MacroGenics Wins $2M Grant For Diabetes Drug

News Archive: 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | View All